Luxembourg's Prince Frederik dead from genetic disease at 22
(NewsNation) — Prince Frederik of Luxembourg has died at 22 from POLG mitochondrial disease, a genetic disorder he has had since birth.
The family announced his death one day after Rare Disease Day, which is the last day of February.
His father, Prince Robert of Luxembourg, posted a statement to the POLG Foundation website, which Prince Frederik founded in 2021 to raise awareness about the rare condition.
Odell Beckham Jr. and Druski accused in assault with Diddy
Prince Frederik was able to say his last goodbyes to his family, including his parents, siblings and cousins, after being able to barely speak for several days.
'He has social skills like no other, an amazing sense of humour, an emotional intelligence and compassion that were off the charts, a sense of justice, fairness and decency that knows no bounds,' Prince Robert said in the statement.
Although Prince Frederik was born with POLG mitochondrial disease, he was not diagnosed until he was 14, when the illness progressed.
The rare disorder affects multiple organ systems and is the most common inherited mitochondrial disease. It is named for the POLG gene, and there are more than 200 POLG mutations that can cause the disease.
Vitamin A won't have 'any impact' on US measles outbreak: Doctor
The POLG Foundation described the disorder as robbing cells of energy and comparing it to a battery that never fully charges, is constantly being depleted and eventually loses power.
There is no cure for POLG diseases, though patients can be given treatment to help manage the symptoms.
Up to 2% of people with Northern European heritage may carry POLG mutations.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
CDC firings: Former director, fired vaccine panelist on RFK Jr's changes
(NewsNation) — While Health and Human Services Secretary Robert F. Kennedy Jr. says he wanted to restore public trust by firing the entire vaccine advisory panel at the Centers for Disease Control and Prevention, one person he fired says Kennedy did the opposite in the academic community. The Advisory Committee on Immunization Practices members was made up of medical and health professionals who made recommendations on the safety and use of vaccines. One of the 17 panelists fired is Dr. Noel Brewer, who joined NewsNation's 'CUOMO' on Tuesday night. 'My concern is that we've taken 60 years of efforts to build trust among health care providers in the recommendations of the advisory committee through CDC, and that trust just evaporated overnight,' Brewer said. 'It is going to be hard to get that back.' The committee was set to meet in two weeks to discuss COVID-19 and other vaccines. Judge determined OPM broke law with DOGE access to data 'I don't think most Americans even care that much about it. And now that there's all this news and people like me out from our ivory towers, it's generating interest,' Brewer said. 'But I don't think that the impact here is going to be primarily among the general public.' Dr. Robert Redfield was CDC director under the first Trump administration, and he said the public lost trust in the power of vaccines. 'I believe vaccines are the most important gift of science to modern medicine. When I was CDC director, I was very disturbed that over half of the population didn't get the flu vaccine,' he said. 'Then, the COVID pandemic came, and I have to say, although I have a lot of respect for Noel and the other people on the committee, the reality is the guidance that came out of the ACIP for COVID vaccines, I think in general, was ill-advised.' Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
6 hours ago
- Yahoo
ClearPoint Neuro, Inc. (CLPT): A Bull Case Theory
We came across a bullish thesis on ClearPoint Neuro, Inc. (CLPT) on M.V. Cunha's Substack. In this article, we will summarize the bulls' thesis on CLPT. ClearPoint Neuro, Inc. (CLPT)'s share was trading at $13.93 as of 6th June. A medical doctor surrounded by advanced technology in the operating room. ClearPoint Neuro is transforming from a surgical tools provider into a critical platform company enabling the next generation of neurological treatments. In the first quarter of 2025, revenue grew 31 percent year-over-year to 8.5 million dollars, led by the rapid adoption of its SmartFrame operating room system, which increased 70 percent and allows hospitals to use ClearPoint technology in standard surgical settings. This expansion seeds a larger installed base and drives high-margin recurring revenue from disposable instruments. The biologics and drug delivery segment generated 4.7 million dollars in revenue, growing 9 percent year-over-year, and is supported by more than 60 active partnerships with gene and cell therapy developers. As these therapies move toward commercial use, ClearPoint's role as the enabling delivery infrastructure could become its most profitable revenue stream, with each procedure generating over 20,000 dollars in high-margin recurring revenue. Meanwhile, the company is intentionally moving away from capital equipment sales, which declined 63 percent, in favor of a subscription-based model that provides predictable recurring revenue. Operating cash burn fell 35 percent in 2024, with expenses rising 29 percent in the latest quarter due to targeted investments in preclinical services, therapy support, and device innovation. ClearPoint closed the quarter with 12.4 million dollars in cash and access to up to 105 million dollars in financing, providing sufficient capital to reach financial breakeven without near-term equity dilution. While risks around execution, partner dependency, and regulatory pacing remain, ClearPoint's embedded position across neurological therapy development offers investors a unique opportunity to benefit from a long-term transformation into the backbone of next-generation brain treatments. Previously, we highlighted a on ClearPoint Neuro from northeasternsvf in January 2025, which emphasized its unique position as the only FDA-cleared, MRI-guided neurosurgical platform enabling precise delivery of CNS gene and cell therapies. That thesis focused on the company's expanding biopharma partnerships, operating room penetration through SmartFrame OR, and its path to profitability via high-margin disposables. ClearPoint Neuro, Inc. (CLPT) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 21 hedge fund portfolios held CLPT at the end of the first quarter which was 13 in the previous quarter. While we acknowledge the risk and potential of CLPT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than CLPT but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey.
Yahoo
6 hours ago
- Yahoo
Hims & Hers Health, Inc. (HIMS) Stock Slides as Market Rises: Facts to Know Before You Trade
Hims & Hers Health, Inc. (HIMS) closed at $55.25 in the latest trading session, marking a -2.83% move from the prior day. This change lagged the S&P 500's 0.55% gain on the day. At the same time, the Dow added 0.25%, and the tech-heavy Nasdaq gained 0.63%. Coming into today, shares of the company had gained 2.99% in the past month. In that same time, the Medical sector gained 3.49%, while the S&P 500 gained 6.29%. Market participants will be closely following the financial results of Hims & Hers Health, Inc. in its upcoming release. The company's upcoming EPS is projected at $0.17, signifying a 183.33% increase compared to the same quarter of the previous year. Our most recent consensus estimate is calling for quarterly revenue of $551.84 million, up 74.83% from the year-ago period. For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $0.73 per share and a revenue of $2.34 billion, representing changes of +170.37% and +58.31%, respectively, from the prior year. Investors should also take note of any recent adjustments to analyst estimates for Hims & Hers Health, Inc. These revisions help to show the ever-changing nature of near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the company's business health and profitability. Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system. The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 5.66% upward. Hims & Hers Health, Inc. is currently a Zacks Rank #2 (Buy). From a valuation perspective, Hims & Hers Health, Inc. is currently exchanging hands at a Forward P/E ratio of 77.39. This valuation marks a premium compared to its industry's average Forward P/E of 27.09. Meanwhile, HIMS's PEG ratio is currently 2.12. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The Medical Info Systems industry had an average PEG ratio of 2.12 as trading concluded yesterday. The Medical Info Systems industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 70, which puts it in the top 29% of all 250+ industries. The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Keep in mind to rely on to watch all these stock-impacting metrics, and more, in the succeeding trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Hims & Hers Health, Inc. (HIMS) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
